HCP Live

Allergy agents popular with both physicians and patients

May 15, 2004

Article

Rapid relief, good safety profile, long-term efficacy are advantages for highly effective drugs

Related Videos

J. Peter Campbell, MD, MPH

Expanding accessibility of vision correction with spectacles for children with cranial abnormalities

Elkin: Talking about the importance of pediatric eye health and safety

Identifying 3 barriers keeping families from accessing cataract treatment for their children in India

Edward Manche, MD

Related Content

Dopavision completes enrollment in trial for the digital treatment of myopia

October 2nd 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Orbis International, Siloam Vision unite to save sight of premature infants using artificial intelligence

September 25th 2023

Managing a changing landscape of IRD pediatric cases

COVID-19 treatment changes infant’s eye color

September 6th 2023

WIO 2023: Cross-linking in pediatric patients: The case for treating keratoconus without waiting for disease progression

August 25th 2023

Dopavision completes enrollment in trial for the digital treatment of myopia

October 2nd 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Orbis International, Siloam Vision unite to save sight of premature infants using artificial intelligence

September 25th 2023

Managing a changing landscape of IRD pediatric cases

COVID-19 treatment changes infant’s eye color

September 6th 2023

WIO 2023: Cross-linking in pediatric patients: The case for treating keratoconus without waiting for disease progression

August 25th 2023

Dopavision completes enrollment in trial for the digital treatment of myopia

October 2nd 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Orbis International, Siloam Vision unite to save sight of premature infants using artificial intelligence

September 25th 2023

Managing a changing landscape of IRD pediatric cases

COVID-19 treatment changes infant’s eye color

September 6th 2023

WIO 2023: Cross-linking in pediatric patients: The case for treating keratoconus without waiting for disease progression

August 25th 2023

Related Content

Dopavision completes enrollment in trial for the digital treatment of myopia

Dopavision completes enrollment in trial for the digital treatment of myopia

ROP: Treating and preventing blindness in preterm babies

ROP: Treating and preventing blindness in preterm babies

Orbis International, Siloam Vision unite to save sight of premature infants using artificial intelligence

Orbis International, Siloam Vision unite to save sight of premature infants using artificial intelligence

Managing a changing landscape of IRD pediatric cases

Managing a changing landscape of IRD pediatric cases

COVID-19 treatment changes infant’s eye color

COVID-19 treatment changes infant’s eye color

WIO 2023: Cross-linking in pediatric patients: The case for treating keratoconus without waiting for disease progression

WIO 2023: Cross-linking in pediatric patients: The case for treating keratoconus without waiting for disease progression

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.